{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T05:23:53Z","timestamp":1794201833438,"version":"4.8.0"},"reference-count":77,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,5,3]]},"DOI":"10.1080\/14796694.2025.2482363","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T02:04:13Z","timestamp":1742954653000},"page":"1333-1348","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":23,"title":["Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2985-4483","authenticated-orcid":false,"given":"Michal","family":"Sternschuss","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center","place":["New York, USA"]},{"name":"Rabin Medical Center","place":["Petah Tikva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center","place":["New York, USA"]},{"name":"Weil Cornell Medical College","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"e_1_3_4_4_1","unstructured":"Cancer of the urinary bladder - cancer stat facts [Internet]. SEER; [cited 2024 Apr 14]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.757"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70275-8"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.03.012"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3571"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.12.029"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01792"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00152-2"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30230-0"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309863"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01643"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02887"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.664"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-00394-5"},{"key":"e_1_3_4_21_1","unstructured":"PADCEV_label.pdf [Internet]. [cited 2024 Jun 15]. Available from: https:\/\/astellas.us\/docs\/PADCEV_label.pdf"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-5581"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02044"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4503"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01369-0"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00844-x"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.818"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00094-2"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e16574"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.016"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2275"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1313"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/his.15130"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1764"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000938"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4175"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.673"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac001"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3738"},{"key":"e_1_3_4_42_1","unstructured":"keytruda_pi.pdf [Internet]. [cited 2024 Jun 16]. Available from: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4532"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.11.012"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30616-2"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01213"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.450"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3089"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231192402"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4070"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000335"},{"key":"e_1_3_4_53_1","first-page":"A1229","article-title":"1187 enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors","author":"Olson D","year":"2022","unstructured":"Olson D, Younan P, Liu B, et al. 1187 enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors. Regul Young Investig Award Abstr [Internet]. 2022 [cited 2024 May 21]:A1229\u2013A1229. Available from: https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-SITC2022.1187","journal-title":"Regul Young Investig Award Abstr"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3380"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4505"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2053"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4562"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA530"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2051"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1326715"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2018-000591"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01547"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4502"},{"key":"e_1_3_4_64_1","unstructured":"Research C for DE. FDA grants accelerated approval to enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial carcinoma [Internet]. FDA; 2023 [cited 2024 May 28]."},{"key":"e_1_3_4_65_1","unstructured":"Research C for DE. FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer [Internet]. FDA; 2023 [cited 2024 May 28]."},{"key":"e_1_3_4_66_1","unstructured":"Inc AP. European Commission approves astellas\u2019 PADCEVTM (enfortumab vedotin) in combination with KEYTRUDA\u00ae (pembrolizumab) for first-line treatment of advanced urothelial cancer [Internet]. [cited 2024 Sep 23]. Available from: https:\/\/www.prnewswire.com\/news-releases\/european-commission-approves-astellas-padcev-enfortumab-vedotin-in-combination-with-keytruda-pembrolizumab-for-first-line-treatment-of-advanced-urothelial-cancer-302232067.html"},{"key":"e_1_3_4_67_1","unstructured":"News | Astellas Pharma Inc. [Internet]. 2024 [cited 2025 Jan 18]. Available from: https:\/\/www.astellas.com\/en\/news\/29451"},{"key":"e_1_3_4_68_1","unstructured":"News | Astellas Pharma Inc [Internet]. 2025 [cited 2025 Jan 18]. Available from: https:\/\/www.astellas.com\/en\/news\/29631"},{"key":"e_1_3_4_69_1","unstructured":"Guidelines Detail [Internet]. NCCN; [cited 2024 Jun 15]. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1417"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.001"},{"key":"e_1_3_4_71_1","unstructured":"EAU Guidelines on MIBC. Introduction - uroweb [internet]. Uroweb - eur. Assoc. Urol. [cited 2024 Jun 15]. Available from: https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308849"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.5534"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.1853"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3927"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6699"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.4.937"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2052"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2482363","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14796694.2025.2482363","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2482363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T05:11:21Z","timestamp":1794201081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2482363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":77,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,5,3]]}},"alternative-id":["10.1080\/14796694.2025.2482363"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2482363","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-08-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}